These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

157 related items for PubMed ID: 19366895

  • 1. Thiopurinemethyltransferase (TPMT) genotype and TPMT activity in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis: relation to azathioprine maintenance treatment and adverse effects.
    Stassen PM, Derks RP, Kallenberg CG, Stegeman CA.
    Ann Rheum Dis; 2009 May; 68(5):758-9. PubMed ID: 19366895
    [No Abstract] [Full Text] [Related]

  • 2. Thiopurine methyltransferase genotype and activity cannot predict outcomes of azathioprine maintenance therapy for antineutrophil cytoplasmic antibody associated vasculitis: A retrospective cohort study.
    Hessels AC, Rutgers A, Sanders JSF, Stegeman CA.
    PLoS One; 2018 May; 13(4):e0195524. PubMed ID: 29630648
    [Abstract] [Full Text] [Related]

  • 3. Role of thiopurine methyltransferase activity in the safety and efficacy of azathioprine in the treatment of pemphigus vulgaris.
    Firooz A, Ghandi N, Hallaji Z, Chams-Davatchi C, Valikhani M, Karbakhsh Davari M.
    Arch Dermatol; 2008 Sep; 144(9):1143-7. PubMed ID: 18794458
    [Abstract] [Full Text] [Related]

  • 4. [Association between metabolic enzyme genotype of azathioprine and drug tolerance in patients with rheumatic diseases].
    Zhan ZP, Liang LQ, Yang XY, Wang YX, Huang M, Li H.
    Zhonghua Yi Xue Za Zhi; 2007 Jul 03; 87(25):1734-7. PubMed ID: 17919375
    [Abstract] [Full Text] [Related]

  • 5. Maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies.
    Sanders JS, Slot MC, Stegeman CA.
    N Engl J Med; 2003 Nov 20; 349(21):2072-3; author reply 2072-3. PubMed ID: 14627795
    [No Abstract] [Full Text] [Related]

  • 6. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis.
    Gelber AC.
    N Engl J Med; 2009 Mar 26; 360(13):1358-9; author reply 1359. PubMed ID: 19330939
    [No Abstract] [Full Text] [Related]

  • 7. Treatment of ANCA-associated vasculitis.
    Langford CA.
    N Engl J Med; 2003 Jul 03; 349(1):3-4. PubMed ID: 12840085
    [No Abstract] [Full Text] [Related]

  • 8. TPMT genotype and its clinical implication in renal transplant recipients with azathioprine treatment.
    Song DK, Zhao J, Zhang LR.
    J Clin Pharm Ther; 2006 Dec 03; 31(6):627-35. PubMed ID: 17176368
    [Abstract] [Full Text] [Related]

  • 9. Prospective evaluation of the pharmacogenetics of azathioprine in the treatment of inflammatory bowel disease.
    Ansari A, Arenas M, Greenfield SM, Morris D, Lindsay J, Gilshenan K, Smith M, Lewis C, Marinaki A, Duley J, Sanderson J.
    Aliment Pharmacol Ther; 2008 Oct 15; 28(8):973-83. PubMed ID: 18616518
    [Abstract] [Full Text] [Related]

  • 10. When should patients with ANCA-associated vasculitis be switched from induction to maintenance therapy?
    Flossmann O, de Groot K.
    Nat Clin Pract Nephrol; 2007 May 15; 3(5):236-7. PubMed ID: 17457358
    [No Abstract] [Full Text] [Related]

  • 11. Should azathioprine and 5-aminosalicylates be coprescribed in inflammatory bowel disease?: an audit of adverse events and outcome.
    Shah JA, Edwards CM, Probert CS.
    Eur J Gastroenterol Hepatol; 2008 Mar 15; 20(3):169-73. PubMed ID: 18301295
    [Abstract] [Full Text] [Related]

  • 12. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis.
    Jourde N, Mancini J, Chiche L.
    N Engl J Med; 2009 Mar 26; 360(13):1358; author reply 1359. PubMed ID: 19321874
    [No Abstract] [Full Text] [Related]

  • 13. Azathioprine hypersensitivity: report of two cases and review of the literature.
    Sinico RA, Sabadini E, Borlandelli S, Cosci P, Di Toma L, Imbasciati E.
    J Nephrol; 2003 Mar 26; 16(2):272-6. PubMed ID: 12768076
    [Abstract] [Full Text] [Related]

  • 14. [New therapeutic strategies in ANCA-associated systemic vasculitis].
    Ruiz FL, Bart PA.
    Rev Med Suisse; 2005 Jan 05; 1(1):19-23. PubMed ID: 15773192
    [Abstract] [Full Text] [Related]

  • 15. Thiopurine S-methyltransferase genotypic analysis in autoimmune bullous diseases.
    Bezier M, Reguiai Z, Vitry F, Broly F, Bernard P.
    Eur J Dermatol; 2008 Jan 05; 18(5):512-7. PubMed ID: 18693152
    [Abstract] [Full Text] [Related]

  • 16. Current use of pharmacogenetic testing: a national survey of thiopurine methyltransferase testing prior to azathioprine prescription.
    Fargher EA, Tricker K, Newman W, Elliott R, Roberts SA, Shaffer JL, Bruce I, Payne K.
    J Clin Pharm Ther; 2007 Apr 05; 32(2):187-95. PubMed ID: 17381669
    [Abstract] [Full Text] [Related]

  • 17. Azathioprine, 6-mercaptopurine and thiopurine S-methyltransferase.
    Roberts-Thomson IC, Butler WJ.
    J Gastroenterol Hepatol; 2005 Jun 05; 20(6):955. PubMed ID: 15946151
    [No Abstract] [Full Text] [Related]

  • 18. Thiopurine dose in intermediate and normal metabolizers of thiopurine methyltransferase may differ three-fold.
    Gardiner SJ, Gearry RB, Begg EJ, Zhang M, Barclay ML.
    Clin Gastroenterol Hepatol; 2008 Jun 05; 6(6):654-60; quiz 604. PubMed ID: 18467186
    [Abstract] [Full Text] [Related]

  • 19. A 6-thioguanine nucleotide threshold level of 400 pmol/8 x 10(8) erythrocytes predicts azathioprine refractoriness in patients with inflammatory bowel disease and normal TPMT activity.
    Roblin X, Peyrin-Biroulet L, Phelip JM, Nancey S, Flourie B.
    Am J Gastroenterol; 2008 Dec 05; 103(12):3115-22. PubMed ID: 19086961
    [Abstract] [Full Text] [Related]

  • 20. Azathioprine-induced fatal myelosuppression in a renal-transplant recipient who carried heterozygous TPMT*1/*3C.
    Tassaneeyakul W, Srimarthpirom S, Reungjui S, Chansung K, Romphruk A, Tassaneeyakul W.
    Transplantation; 2003 Jul 15; 76(1):265-6. PubMed ID: 12865824
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.